Back to Agenda
Session 8: Innovative Designs for Acute Myeloid Leukemia: Patient, Sponsor, and Investigator Perspectives
Session Chair(s)
Robert A. Beckman, MD
Professor of Oncology and of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, United States
The session will introduce the audience to two innovative clinical study designs for acute myeloid leukemia (AML), a highly personalized complex innovative design (Multiomic Precision Medicine) and a master protocol (BEAT AML), and culminate in a panel discussion which will use these examples to illuminate master protocols and other complex innovative designs from the perspectives of patients, trial participants, sponsors, and investigators.
Learning Objective : - Understand the concept of highly personalized complex innovative designs (CID) & master trials
- Understand how patients & trial participants view highly personalized CID & master protocols including benefits & pitfalls
- Understand how investigators work with patient communities & trial participants when designing & executing master protocols & highly personalized CID
- Understand the view of the Sponsor in a highly personalized CID or master protocol
Speaker(s)
Amy Burd, PHD
Chief Scientific Officer, Eilean Therapeutics, United States
Precision Medicine Treatment in Older AML
Pamela Becker, MD, PHD
Professor of Clinical Medicine, University of California Irvine, United States
Multi-Omic and Functional Drug Screening Approach to Treatment Selection in AML
Uma Borate, MD
Associate Professor, The Ohio State University, United States
Speaker
Kevin Harrang
Founder & Board Member, Metajure, Inc., United States
Speaker
Jorge DiMartino, MD, PHD
Chief Medical Officer, Kronos Bio, United States
Speaker
Ken Dixon, MD
Founder, Chief Medical Officer, specicare, United States
Speaker
Crystal Reinhart, PHD
Center for Prevention Research and Development, School of Social Work, University of Illinois at Urbana-Champaign, United States
Speaker
Have an account?